SRD5A2
3-oxo-5-alpha-steroid 4-dehydrogenase 2
As of the edition of 20 October 2026, SRD5A2 (3-oxo-5-alpha-steroid 4-dehydrogenase 2, UniProt P31213) has 4 drugs tested at it and 7 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31213
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Urinary and reproductive; Cancer; Skin and connective tissue; Pregnancy and women's health; Hormones; Chemically induced; Nervous system; Digestive system
- Registered trials of its drugs
- 233
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Abiraterone | Marketed | Phase 4 | none listed |
| Dutasteride | Marketed | Phase 4 | none listed |
| Finasteride | Marketed | Phase 4 | none listed |
| DKF-313 | Active | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| GSK | Route B |
| Waylis Therapeutics | Route B |
| Organon | Route B |
The other 4 companies at SRD5A2
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at SRD5A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.